Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.375 EUR | +3.00% | +10.89% | +58.41% |
2023 | Medesis Pharma S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
2023 | MEDESIS : Invest Securities confirms its recommendation | CF |
Sales 2021 | 95.73K 103K | Sales 2022 | 197K 212K | Capitalization | 8.68M 9.32M |
---|---|---|---|---|---|
Net income 2021 | -2M -2.15M | Net income 2022 | -2M -2.15M | EV / Sales 2021 | 219 x |
Net cash position 2021 | 1.61M 1.72M | Net Debt 2022 | 1.08M 1.16M | EV / Sales 2022 | 49.4 x |
P/E ratio 2021 |
-8.52
x | P/E ratio 2022 |
-3.16
x | Employees | 10 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 80.97% |
1 day | +3.00% | ||
1 week | +10.89% | ||
Current month | +10.89% | ||
1 month | +1.10% | ||
3 months | +78.57% | ||
6 months | +56.25% | ||
Current year | +58.41% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 03-04-02 | |
Solene Guilliot
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Mario Alcaraz
SEC | Corporate Secretary | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | - | 19-06-11 | |
Robert Alonso
BRD | Director/Board Member | - | 22-10-26 |
Walt Linscott
BRD | Director/Board Member | 63 | 22-10-26 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 1.375 | +3.00% | 4,325 |
24-05-07 | 1.335 | -4.64% | 5,533 |
24-05-06 | 1.4 | +16.67% | 36,447 |
24-05-03 | 1.2 | -3.61% | 5,794 |
24-05-02 | 1.245 | +0.40% | 232 |
Real-time Euronext Paris, May 08, 2024 at 11:35 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+58.41% | 6.37M | |
+2.93% | 106B | |
+7.02% | 23.47B | |
-14.60% | 21.9B | |
-7.05% | 18.77B | |
-38.55% | 17.85B | |
-8.83% | 16.78B | |
+5.51% | 14.41B | |
+37.49% | 12.86B | |
+329.39% | 8.78B |
- Stock Market
- Equities
- ALMDP Stock